New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
07:34 EDTINCYIncyte duration of response not an issue, says Jefferies
Jefferies says the shorter than expected duration of response for Incyte's '360 with ipilimumab is not an issue since the progression-free survival number is strong. Jefferies believes last night's data suggests that '360 offers up to three times the clinical benefit expected with ipilimumab alone. It maintains a Buy rating on Incyte shares with an $80 price target.
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 12, 2014
08:01 EDTINCYPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 9, 2014
07:11 EDTINCYEli Lilly and Incyte announce Phase 3 RA-BEACON study met primary endpoint
Subscribe for More Information
December 8, 2014
13:07 EDTINCYNovartis announces data from Jakavi trial
Novartis (NVS) announced data from the largest clinical trial of myelofibrosis patients treated with Jakavi, supporting the safety profile and efficacy benefit as measured in primary and secondary endpoints respectively. In an analysis of 1,144 patients treated with Jakavi to date in this ongoing expanded access study, 69% of patients achieved >50% reduction in spleen size from baseline and patients also experienced a clinically meaningful improvement in myelofibrosis symptom score, important treatment goals for patients with myelofibrosis. Findings from the study were presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, California. Novartis research and development efforts, in collaboration with Incyte Corporation (INCY), include early-phase and post-marketing studies in myelofibrosis and other myeloproliferative neoplasms. More than 50 abstracts on ruxolitinib are being presented at ASH, including three oral presentations exploring combinations of ruxolitinib with various investigational compounds, evaluating the possibility of simultaneously targeting multiple cancer pathways that may be involved in the pathogenesis of myelofibrosis. The JUMP study is a Phase IIIb, expanded-access trial for countries with no access to Jakavi outside of a clinical trial. The open-label, multicenter study analyzed 1,144 enrolled myelofibrosis patients who received daily starting doses of either 5 mg, 15 mg or 20 mg of Jakavi twice daily based on platelet counts at baseline. The primary endpoint is assessment of safety and tolerability of Jakavi. Overall, the safety and efficacy profile of Jakavi was consistent with previous studies.
December 5, 2014
16:40 EDTINCYDiplomat Pharmacy: FDA approves expanded indication of Jakafi
Subscribe for More Information
09:49 EDTINCYIncyte polycythemia vera approval another upside driver, says UBS
Subscribe for More Information
07:16 EDTINCYFDA PDUFA Date for Incyte's Jakafi (Ruxolitinib) is December 5, 2014
Subscribe for More Information
December 4, 2014
10:49 EDTINCYFDA approves Jakafi to treat polycythemia vera
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use